

# Press Release

## **OmniComm Systems (TrialMaster®) and Catalyst Pharmaceutical Research Team-Up to Expedite Phase I Trial Data Collection and Reporting**

**Ft. Lauderdale, Florida – September 3, 2004 - /MarketWire/**

OmniComm Systems, Inc. one of the fastest growing companies in the EDC marketplace announced today that it has entered into a strategic partnership with Catalyst Pharma Group Inc. The TrialMaster® system, the core product of OmniComm, provides Catalyst and trial sponsors with a 21 CFR Part 11 compliant Internet-based data and trial management solution that greatly increases the efficiency, security and integrity of clinical research data and thus significantly reduces the time and expense involved in conducting clinical studies. Catalyst is a full service contract research organization (CRO) focused on helping companies with limited presence in the U.S. develop their products and navigate regulatory channels in obtaining FDA approval.

OmniComm will provide its Web-based electronic data capture ("EDC") solution, TrialMaster® and related value-added EDC services to Catalyst's clients at its Healthcare Discoveries Inc. (HD) Phase I research unit in San Antonio, Texas. Catalyst is in the process of evaluating TrialMaster® for later phase trials as well.

The company selected OmniComm Systems after an extensive review of several technology providers and their products. According to Dennis Ruff, MD, President of Healthcare Discoveries, OmniComm offers a flexible and easy to use trial and data capture solution, superior professional services and a technology infrastructure that will support the company's growing request for EDC capabilities. Catalyst's CEO, Richard Anthony, added, "whether making dose escalation decisions or crucial Go-No-Go decisions, providing our Sponsor clients access to timely data, is critical for making sound decisions, OmniComm Systems provides us with a easy to navigate and cost effective trial and data capture solution that is capable of meeting the unique demands of early stage studies."

"TrialMaster® has been recognized by Pharmaceutical and biotech companies as the ideal EDC solution for Phase I trials. Optimized for flexibility and ease of use, TrialMaster® reduces site burden while helping produce better data faster for Sponsors" said OmniComm System's CEO, Cornelis Wit. Catalyst CEO Richard Anthony agrees, "We are exited about having OmniComm Systems as a technology partner which will enable each of us to provide new and proven resources for our mutual and prospective clients. Both companies are known for their regulatory-sound, budget-responsible approach to their business. We look forward to a long and mutually beneficial relationship."

### **About Catalyst Pharma Group Inc.**

Catalyst Pharma Group is the parent company of Catalyst Pharmaceutical Research LLC of Pasadena, California ([www.catalystpharma.com](http://www.catalystpharma.com)) and Healthcare Discoveries Inc. of San Antonio, Texas ([www.healthcare-discoveries.com](http://www.healthcare-discoveries.com)). Catalyst Pharmaceutical Research LLC is a contract research organization (CRO) providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies worldwide. Healthcare

Discoveries is a fully staffed 50 bed dedicated clinical research unit. HD has an extensive health volunteer database as well as access to special volunteer populations such as diabetics, ESRD, asthmatics, and hypertensives. HD has experience with all aspects of Phase I studies including PK/PD studies, bioavailability and drug interaction studies.

### **About OmniComm Systems, Inc.**

OmniComm Systems, Inc. ([www.omnicomm.com](http://www.omnicomm.com)) is one of the fastest growing companies in the EDC market place targeting its product TrialMaster® to the pharmaceutical, medical device and biotechnology companies as well as CRO's. OmniComm's growing base of satisfied customers is a direct result of OmniComm's employee's commitment to on-time, quality and within budget performance.

The TrialMaster® ([www.trialmaster.com](http://www.trialmaster.com)) system, the core product of OmniComm, utilizes Microsoft's .NET architecture providing users with a new level of integration and communication within the clinical trial environment. TrialMaster® is recognized by clinical research and study site personnel as being a highly intuitive and flexible data capture and trial management solution.

### **Safe Harbor Disclaimer**

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

For more info, please contact Rusty Beardsley, Sr. VP Marketing and Sales, OmniComm Systems, Inc., 215-542-8828, [rbeardsley@omnicomm.com](mailto:rbeardsley@omnicomm.com).